{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T01:23:46Z","timestamp":1766712226408,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Treatment resistant psychiatric disorders affect millions of people across the globe. Ketamine has been employed as a treatment option for those with treatment resistant depression, as well as for chronic pain and alcohol use disorder. However, case presentations and research has been limited on the outcomes, and furthermore there is even less on the patient or caregiver perspective on the impact of the treatment. Case Presentation: Here, we present a middle-aged male who has undergone 20 intravenous (IV) ketamine infusions to treat Complex Post-Traumatic Stress Disorder (C-PTSD) and Major Depressive Disorder (MDD). We provide both qualitative perspectives from the patient, caregiver, as well as quantitative analyses of the patient from the Patient Health Questionnaire-9 (PHQ9), Beck\u2019s Depression Inventory (BDI), and the Neurobehavioral Symptom Inventory (NSI) following treatment and weekly (4 weeks) assessments between treatments. Conclusions: Collectively, these data provide a holistic view of the use of ketamine for this patient on a variety of mental health, physiological, and behavioral conditions.<\/jats:p>","DOI":"10.3390\/reports8010013","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:50:53Z","timestamp":1737525053000},"page":"13","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Quantitative and Qualitative Analysis of the Patient and Caregiver\u2019s Perspective on Outcomes of Intravenous Administration of Low-Dose Ketamine for C-PTSD, TBI, and Treatment Resistant MDD: A Clinical Example"],"prefix":"10.3390","volume":"8","author":[{"given":"Laura","family":"Hentig","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of Colorado-Colorado Springs, Colorado Springs, CO 80918, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Hentig","sequence":"additional","affiliation":[{"name":"School of Nursing, Johns Hopkins University, Baltimore, MD 21205, USA"},{"name":"School of Public Health, Brown University, Providence, RI 02912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica M.","family":"Gill","sequence":"additional","affiliation":[{"name":"School of Nursing, Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e0174847","DOI":"10.1371\/journal.pone.0174847","article-title":"Mild Traumatic Brain Injury (mTBI) and chronic cognitive impairment: A scoping review","volume":"12","author":"McInnes","year":"2017","journal-title":"PLoS ONE"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/16501960410023732","article-title":"Incidence, risk factors and prevention of mild traumatic brain injury: Results of the who collaborating centre task force on mild traumatic brain injury","volume":"36","author":"Cassidy","year":"2004","journal-title":"J. Rehabil. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/S1355617705050277","article-title":"Factors moderating neuropsychological outcomes following mild traumatic brain injury: A meta-analysis","volume":"11","author":"Belanger","year":"2005","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1089\/neu.2016.4618","article-title":"Mild Traumatic Brain Injury: Longitudinal Study of Cognition, Functional Status, and Post-Traumatic Symptoms","volume":"34","author":"Dikmen","year":"2017","journal-title":"J. Neurotrauma"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hellewell, S.C., Beaton, C.S., Welton, T., and Grieve, S.M. (2020). Characterizing the Risk of Depression Following Mild Traumatic Brain Injury: A Meta-Analysis of the Literature Comparing Chronic mTBI to Non-mTBI Populations. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00350"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/neu.2021.0111","article-title":"Incidence of Depression after Traumatic Brain Injury: A Nationwide Longitudinal Study of 2.2 Million Adults","volume":"39","author":"Choi","year":"2022","journal-title":"J. Neurotrauma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/02699052.2017.1376756","article-title":"Prevalence of depression after TBI in a prospective cohort: The SHEFBIT study","volume":"32","author":"Singh","year":"2017","journal-title":"Brain Inj."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/postgradmedj-2019-136860","article-title":"Association between suicide risk and traumatic brain injury in adults: A population based cohort study","volume":"96","author":"Lu","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kvam, T.-M., Goks\u00f8yr, I.W., Stewart, L.H., Repantis, D., R\u00f8ssberg, J.I., and Andreassen, O.A. (2022). Study protocol for \u201cMDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study\u201d. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.954388"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: A review","volume":"2","author":"Yavi","year":"2022","journal-title":"Discov. Ment. Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/02791072.1980.10471430","article-title":"History and Pharmacology of PCP and PCP-Related Analogs","volume":"12","author":"Domino","year":"1980","journal-title":"J. Psychedelic Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.4088\/JCP.17f11738","article-title":"Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17m11731","DOI":"10.4088\/JCP.17m11731","article-title":"Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital","volume":"79","author":"Wilkinson","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12094","article-title":"Ketamine for chronic pain: Risks and benefits","volume":"77","author":"Niesters","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","article-title":"Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression","volume":"155","author":"Shiroma","year":"2013","journal-title":"J. Affect. Disord."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/1\/13\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:33:31Z","timestamp":1759919611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/1\/13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["reports8010013"],"URL":"https:\/\/doi.org\/10.3390\/reports8010013","relation":{},"ISSN":["2571-841X"],"issn-type":[{"type":"electronic","value":"2571-841X"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}